Company logo

KPTI - Karyopharm Therapeutics Inc.

NASDAQ -> Healthcare -> Biotechnology
Newton, United States
Type: Equity

KPTI price evolution
KPTI
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $85.11 $31.39 $53.19
Short term investments $67.35 $117.95 $139.21
Net receivables $31.78 $37.99 $31.08 $26.96
Inventory $4.67 $3.48 $2.77 $3.04
Total current assets $184.75 $208.54 $198.37 $233.92
Long term investments
Property, plant & equipment $3.08 $3.8 $4.45 $4.88
Goodwill & intangible assets
Total noncurrent assets $5.44 $6.09 $6.52
Total investments $67.35 $117.95 $139.21
Total assets $189.48 $213.98 $204.46 $240.44
Current liabilities
Accounts payable $5.78 $2.8 $5.03 $3.12
Deferred revenue
Short long term debt $3.54 $3.42 $3.31
Total current liabilities $61.49 $57.62 $65.34 $69.48
Long term debt $264.09 $192.09 $173.01 $173.71
Total noncurrent liabilities $288.5 $308.07 $307.17
Total debt $195.63 $176.44 $177.02
Total liabilities $349.12 $346.12 $373.41 $376.64
Shareholders' equity
Retained earnings -$1532.68 -$1500.61 -$1524.4 -$1487.04
Other shareholder equity -$0.22 -$0.6 -$0.52 -$0.16
Total shareholder equity -$132.14 -$168.96 -$136.21
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $53.19 $136.88 $197.44 $89.12
Short term investments $139.21 $142.78 $38.16 $163.32
Net receivables $26.96 $47.09 $22.5 $12.88
Inventory $3.04 $4.22 $4.11 $2.64
Total current assets $233.92 $350.16 $275.61 $276.53
Long term investments $24.21
Property, plant & equipment $4.88 $7.38 $9.56 $11.58
Goodwill & intangible assets
Total noncurrent assets $6.52 $8.01 $29.7 $36.52
Total investments $139.21 $142.78 $38.16 $187.54
Total assets $240.44 $358.17 $305.31 $313.05
Current liabilities
Accounts payable $3.12 $2.77 $1.6 $4.45
Deferred revenue $0.3
Short long term debt $3.31 $2.87 $2.32 $1.92
Total current liabilities $69.48 $65.91 $73.72 $60.2
Long term debt $173.71 $302.82 $178.26 $129.21
Total noncurrent liabilities $307.17 $308.92 $311.26 $202.3
Total debt $177.02 $179.07 $180.58 $131.13
Total liabilities $376.64 $374.83 $384.98 $262.5
Shareholders' equity
Retained earnings -$1487.04 -$1343.94 -$1178.65 -$1069.61
Other shareholder equity -$0.16 -$0.64 $0.19 $0.52
Total shareholder equity -$136.21 -$16.66 -$79.67 $50.55
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $38.78 $42.79 $33.13 $33.75
Cost of revenue $1.47 $1.91 $1.49
Gross Profit $37.48 $41.32 $31.21 $32.26
Operating activities
Research & development $38.37 $35.42 $39.38
Selling, general & administrative $31.07 $29.55 $30.69
Total operating expenses $63.77 $69.44 $64.97 $70.07
Operating income -$28.12 -$33.76 -$37.81
Income from continuing operations
EBIT $32.81 -$31.41 -$35.5
Income tax expense $0.03 $0.07 $0.07 $0.13
Interest expense -$9.55 $8.95 $5.88 $6.21
Net income
Net income -$32.07 $23.79 -$37.36 -$41.84
Income (for common shares) $23.79 -$37.36 -$41.84
(in millions $) 31 Dec 2023 31 Dec 2022 31 Jan 2022 31 Dec 2020
Revenue
Total revenue $146.03 $157.07 $108.08
Cost of revenue $4.94 $5.21 $2.71
Gross Profit $141.09 $151.86 $105.38
Operating activities
Research & development $138.75 $148.66 $150.81
Selling, general & administrative $131.88 $145.4 $126.42
Total operating expenses $270.63 $294.06 $277.23
Operating income -$129.54 -$142.2 -$171.85
Income from continuing operations
EBIT -$118.95 -$139.93 -$168.82
Income tax expense $0.32 $0.37 $0.31
Interest expense $23.82 $25 $27.14
Net income
Net income -$143.1 -$165.29 -$196.27
Income (for common shares) -$143.1 -$165.29 -$196.27
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income $23.79 -$37.36 -$41.84
Operating activities
Depreciation $0.09 $0.09 $0.08
Business acquisitions & disposals
Stock-based compensation $5.41 $4.97 $5.18
Total cash flows from operations -$38.5 -$43.73 -$18.59
Investing activities
Capital expenditures -$0.2
Investments $51.26 $22.14 $26.84
Total cash flows from investing $80.68 $51.26 $21.94 $26.84
Financing activities
Dividends paid
Sale and purchase of stock $0.26
Net borrowings
Total cash flows from financing $40.97 $0.26
Effect of exchange rate $0.01 -$0.01 -$0.02 $0.09
Change in cash and equivalents $19.98 $53.72 -$21.8 $8.61
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$143.1 -$165.29 -$124.09 -$196.27
Operating activities
Depreciation $0.53 $0.62 $0.79 $0.97
Business acquisitions & disposals
Stock-based compensation $21.71 $35.4 $29.78 $24.41
Total cash flows from operations -$92.72 -$149.55 -$107.12 -$160.23
Investing activities
Capital expenditures -$0.12 -$0.21 -$0.14
Investments $7.94 -$104.14 $147.55 -$53.54
Total cash flows from investing $7.94 -$104.26 $141.84 -$53.69
Financing activities
Dividends paid
Sale and purchase of stock $1.12 $193.74 $13.65 $172.08
Net borrowings $60
Total cash flows from financing $1.12 $193.74 $73.65 $172.08
Effect of exchange rate -$0.03 -$0.49 -$0.05 $0.27
Change in cash and equivalents -$83.69 -$60.56 $108.32 -$41.57
Fundamentals
Market cap $79.57M
Enterprise value N/A
Shares outstanding 125.30M
Revenue $148.44M
EBITDA N/A
EBIT N/A
Net Income -$87.48M
Revenue Q/Q 7.70%
Revenue Y/Y 1.77%
P/E ratio -0.91
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 0.54
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.70
ROA -41.25%
ROE N/A
Debt/Equity -2.77
Net debt/EBITDA N/A
Current ratio 3.00
Quick ratio 2.93